Sorriso Pharmaceuticals, a Salt Lake City, UT-based company focused on transforming anti-inflammatory antibody therapy, closed on a $31m Series A financing.
The round was co-led by New Enterprise Associates (NEA), and Arix Bioscience plc. In conjunction with the financing, Ed Mathers, general partner at NEA, and Mark Chin, managing director at Arix Bioscience, joined Sorriso’s board of directors.
The company intends to use the funds to advance its pipeline of novel oral antibodies to address unmet needs in immune- mediated diseases.
Led by Ciara Kennedy, president, and CEO, Sorriso Pharmaceuticals is a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn’s disease and ulcerative colitis. The platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the intestinal system. The lead program is SOR102, in development for the treatment of inflammatory bowel disease (IBD). SOR102 simultaneously inhibits TNFa and IL-23, two clinically validated drivers of IBD. This unique approach combines the clinical impact of injectable antibody therapeutics with the benefits of oral administration, resulting in targeted activity, negligible systemic exposure, and minimal immunogenicity.
